Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference




Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

EDMONTON, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

The video webcast presentation will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company’s website (www.ceapro.com) and will be archived for 90 days following the event.

For more information about the event, please visit the conference website here.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release